MEMPHIS, Tenn.--(BUSINESS WIRE)--GTx Inc. (Nasdaq: GTXI) today announced that additional study results from clinical trials evaluating Ostarine™ (GTx-024) for the treatment of cancer cachexia and toremifene 80 mg for the reduction of fractures in men with prostate cancer on androgen deprivation therapy (ADT) will be presented at the 2010 American Society of Clinical Oncology (ASCO) Annual Meeting being held June 4 – 8 at McCormick Place in Chicago.
